William T. Longstreth

William T. Longstreth

Auto-generated profile, based on publicly available information

William T. Longstreth

Departments of Neurology and Epidemiology, University of Washington, Seattle, WA 98195, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 March 2013 in Stroke
Verified
Journal Article
Closed access
PDF file
WLW.T. Longstreth
W.T. Longstreth
RKRichard A. Kronmal
Richard A. Kronmal
JTJohn L.P. Thompson
John L.P. Thompson
RCRobert H. Christenson
Robert H. Christenson
SLSteven R. Levine
Steven R. Levine
CDChristopher R. Defilippi
Christopher R. Defilippi
Background and Purpose—: Because of its association with atrial fibrillation and heart failure, we hypothesized that amino terminal pro–B-type natriuretic peptide (NT-proBNP) would identify a subgroup of patients from the Warfarin–Aspirin Recurrent Stroke Study, diagnosed with inferred noncardioembolic ischemic strokes, where anticoagulation would be more effective than antiplatelet agents in reducing risk of subsequent events. Methods—: NT-proBNP was measured in stored serum collected at baseline from participants enrolled in Warfarin–Aspirin Recurrent Stroke Study, a previously reported randomized trial. Relative effectiveness of warfarin and aspirin in preventing recurrent ischemic stroke or death over 2 years was compared based on NT-proBNP concentrations. Results—: About 95% of 1028 patients with assays had NT-proBNP below 750 pg/mL, and among them, no evidence for treatment effect modification was evident. For 49 patients with NT-proBNP >750 pg/mL, the 2-year rate of events per 100 person-years was 45.9 for the aspirin group and 16.6 for the warfarin group, whereas for 979 patients with NT-proBNP ≤750 pg/mL, rates were similar for both treatments. For those with NT-proBNP >750 pg/mL, the hazard ratio was 0.30 (95% confidence interval: 0.12–0.84; P =0.021) significantly favoring warfarin over aspirin. A formal test for interaction of NT-proBNP with treatment was significant ( P =0.01). Conclusions—: For secondary stroke prevention, elevated NT-proBNP concentrations may identify a subgroup of ischemic stroke patients without known atrial fibrillation, about 5% based on the current study, who may benefit more from anticoagulants than antiplatelet agents. Clinical Trial Registration—: This trial was not registered because enrollment began before 2005.

1 May 2010 in Resuscitation
Verified
Journal Article
Closed access
WLW.T. Longstreth
W.T. Longstreth
GNGraham Nichol
Graham Nichol
LOLois Van Ottingham
Lois Van Ottingham
AHAlfred P. Hallstrom
Alfred P. Hallstrom

3 January 2021 in Social Psychiatry and Psychiatric Epidemiology
Verified
Journal Article
Closed access
PDF file
Lilah BesserLilah Besser
Lilah Besser
GLGina S. Lovasi
Gina S. Lovasi
YMYvonne L Michael
Yvonne L Michael
PGParveen Garg
Parveen Garg
JHJana Hirsch
Jana Hirsch
WLW. T. Longstreth
W. T. Longstreth

29 January 2019 in Neurology
Verified
Journal Article
Open access
PDF file
GCGanesh Chauhan
Ganesh Chauhan
HAHieab H.H. Adams
Hieab H.H. Adams
CSClaudia L. Satizabal
Claudia L. Satizabal
JBJoshua C. Bis
Joshua C. Bis
ATAlexander Teumer
Alexander Teumer
SDStéphanie Debette
Stéphanie Debette
Objective To explore genetic and lifestyle risk factors of MRI-defined brain infarcts (BI) in large population-based cohorts. Methods We performed meta-analyses of genome-wide association studies (GWAS) and examined associations of vascular risk factors and their genetic risk scores (GRS) with MRI-defined BI and a subset of BI, namely, small subcortical BI (SSBI), in 18 population-based cohorts (n = 20,949) from 5 ethnicities (3,726 with BI, 2,021 with SSBI). Top loci were followed up in 7 population-based cohorts (n = 6,862; 1,483 with BI, 630 with SBBI), and we tested associations with related phenotypes including ischemic stroke and pathologically defined BI. Results The mean prevalence was 17.7% for BI and 10.5% for SSBI, steeply rising after age 65. Two loci showed genome-wide significant association with BI: FBN2, p = 1.77 × 10−8; and LINC00539/ZDHHC20, p = 5.82 × 10−9. Both have been associated with blood pressure (BP)–related phenotypes, but did not replicate in the smaller follow-up sample or show associations with related phenotypes. Age- and sex-adjusted associations with BI and SSBI were observed for BP traits (p value for BI, p[BI] = 9.38 × 10−25; p[SSBI] = 5.23 × 10−14 for hypertension), smoking (p[BI] = 4.4 × 10−10; p[SSBI] = 1.2 × 10−4), diabetes (p[BI] = 1.7 × 10−8; p[SSBI] = 2.8 × 10−3), previous cardiovascular disease (p[BI] = 1.0 × 10−18; p[SSBI] = 2.3 × 10−7), stroke (p[BI] = 3.9 × 10−69; p[SSBI] = 3.2 × 10−24), and MRI-defined white matter hyperintensity burden (p[BI] = 1.43 × 10−157; p[SSBI] = 3.16 × 10−106), but not with body mass index or cholesterol. GRS of BP traits were associated with BI and SSBI (p ≤ 0.0022), without indication of directional pleiotropy. Conclusion In this multiethnic GWAS meta-analysis, including over 20,000 population-based participants, we identified genetic risk loci for BI requiring validation once additional large datasets become available. High BP, including genetically determined, was the most significant modifiable, causal risk factor for BI.

11 January 2018 in Neuroepidemiology
Verified
Journal Article
Closed access
PDF file
WJW.T. Longstreth Jr.
W.T. Longstreth Jr.
NGNatalie C. Gasca
Natalie C. Gasca
RGRebecca F. Gottesman
Rebecca F. Gottesman
JPJohn B. Pearce
John B. Pearce
RSRalph L. Sacco
Ralph L. Sacco
Background: To describe adjudication of transient ischemic attack (TIA) and stroke in an observational study. Methods: We detail the process used to adjudicate TIA and stroke in the Multi-Ethnic Study of Atherosclerosis (MESA), a large longitudinal cohort study. Two of three vascular neurologists adjudicated each event using specific protocols. We examined the initial agreement, effect of imaging on diagnosis of TIA versus ischemic stroke, and effect of strict and less strict criteria on the number of ischemic stroke subtypes classified as undetermined. Results: Of 573 adjudicated events over 13.5 years of follow-up, 95 (16.5%) had TIA and 269 (47.0%) had stroke: 211 (78.4%) ischemic, 43 (16.0%) hemorrhagic, and 15 (5.6%) other. Disagreements occurred on 16% of initial adjudication of events. Using results from imaging, the number with TIA decreased by 8.6% and with ischemic stroke increased by 4.1%. Using less strict criteria to classify ischemic stroke subtypes reduced the number classified as undetermined, from 137 to 59, and numbers classified as cardioembolic and small vessel doubled. Conclusions: We hope that this work will motivate and facilitate investigators to use MESA data to investigate issues concerning TIA and stroke and will inform investigators seeking to adjudicate TIA and stroke in other studies.

25 September 2014 in Movement Disorders
Verified
Journal Article
Closed access
PDF file
JLJessica I. Lundin
Jessica I. Lundin
TTThanh G.N. Ton
Thanh G.N. Ton
ALAndrea Z. LaCroix
Andrea Z. LaCroix
WLW.T. Longstreth
W.T. Longstreth
GFGary M. Franklin
Gary M. Franklin
HCHarvey Checkoway
Harvey Checkoway